Skip to main content
. 2015 Mar 16;6(11):9125–9139. doi: 10.18632/oncotarget.3273

Figure 5. Inhibition of miR-155 decreases proliferation, migration, and invasion of chordoma cells.

Figure 5

(A, B) Cell proliferation assay results for U-CH1 cells transfected with miR-155 inhibitor at concentrations between 0 nM and 80 nM, and incubated for 24–96 h. (C, D) miR-155 antagonism resulted in the inhibition of the migratory activity of U-CH1 chordoma cells after transfection with either miR-155 or non-specific miR inhibitor at 40 nM. (C) micrographs of chordoma U-CH1 cells at 0 h, 8 h and 24 h after wounding. (D) The coverage rate of U-CH1 cells for each time point and condition in the wound healing assay. (E, F) Invasive activity assay results for U-CH1 cells transfected with miR-155 inhibitor. (E) Micrographs of chordoma U-CH1 cells transfected with 40 nM miR-155 inhibitor. (F) Average numbers of invasive chordoma cells among those transfected with 10–80 nM miR-155. *p < 0.01.